Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* Persistent bronchial asthma~* No change in asthma treatment within 4 weeks prior to visit 1~* Non-smoker or ex-smoker (for 12 months or longer)~Main Exclusion Criteria:~* Poorly controlled asthma or seasonal asthma~* History of lower airway infection four weeks prior to visit 1~* Chronic obstructive pulmonary disease (COPD) and/or other relevant lung disease~* Patients using \> 8-puffs/day-short-acting bronchodilator (beta-agonists) (more than 3 days per week on average) prior to visit 1~* Clinically relevant abnormal laboratory values suggesting an undiagnosed disease, severe renal insufficiency, active hepatitis or an HIV infection~* Diagnosis, treatment or remission of any cancer (other than basal cell carcinoma) within two years prior to visit 1~* Patients with chronic heart failure~* Suspected hypersensitivity and/or contraindication to roflumilast or albuterol/salbutamol~* Female patients of childbearing potential not using adequate means of birth control or pregnant or breast-feeding females~* Patients who have received any investigational medication or device in the month prior to visit 1 or who plan to use another investigational medication during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).